Miami Cancer Institute appoints deputy director
Source/Disclosures Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS
You ve successfully added to your alerts. You will receive an email when new content is published.
Back to Healio
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Back to Healio
Manmeet Ahluwalia, MD, FACP, MBA, has been appointed deputy director of Baptist Health’s Miami Cancer Institute.
Ahluwalia a neuro-oncologist whose research focuses on primary brain tumors and brain metastases also will serve as chief scientific officer and chief of solid tumor medical oncology.
Blue Earth Diagnostics Announces Dosing of Initial Patient in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases
Clinical utility of Axumin (fluciclovine F 18) being investigated in expanded areas of cancer imaging
Getty Images
January 18, 2021 Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced that the first patient has been dosed in its Phase 3 REVELATE clinical trial of 18F-fluciclovine, a positron emission tomography (PET) imaging radiopharmaceutical being studied for potential use in detecting recurrent brain metastases. The REVELATE study is a Phase 3, multi-center, single-arm imaging study being conducted in the United States. Its purpose is to assess the diagnostic performance of 18F-fluciclovine PET in detecting recurrent brain metastases in patients previously treated with radiation therapy. The firs
(1)
- Clinical utility of Axumin (fluciclovine F 18) being investigated in expanded areas of cancer imaging -
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced that the first patient has been dosed in its Phase 3 REVELATE clinical trial of
18F-fluciclovine, a positron emission tomography (PET) imaging radiopharmaceutical being studied for potential use in detecting recurrent brain metastases. The REVELATE study is a Phase 3, multi-center, single-arm imaging study being conducted in the United States. Its purpose is to assess the diagnostic performance of
18F-fluciclovine PET in detecting recurrent brain metastases in patients previously treated with radiation therapy. The first patient dosed in the study was at Yale University, New Haven, Conn., under the auspices of Dr. Mariam Aboian, Assistant Professor of Radiology.
Meaningful Exploration & Discovery
A great university defines success by how it advances humanity through academic, scholarly and social leadership. By that standard, Tulane is truly impactful and ascendant. Tulane’s manifold contributions are evident in the lives we transform, the problems we solve and the community we foster.
IN FY20, TULANE RECEIVED MORE THAN $176 MILLION IN RESEARCH FUNDING THE HIGHEST AMOUNT IN TULANE’S HISTORY.
Health Equality
THOMAS LAVEIST, a national expert on issues related to equity and health, is dean of Tulane University’s School of Public Health and Tropical Medicine and the Weatherhead Presidential Chair in Health Equity. He and other key researchers are currently working to launch a new Health Equity Institute, to study how health issues disproportionately impact the Black community. LaVeist is also co-chair of the Louisiana COVID-19 Health Equity Task Force, which was tasked by Gov. John Bel Edwards to develop a series of recomme
James Bernal / The Hechinger Report
Originally published on December 21, 2020 4:02 pm
At a time when the pandemic has exposed a growing shortage of nurses, it should have been good news that there were more than 1,200 applicants to enter the associate degree program in nursing at Long Beach City College.
But the California community college took only 32 of them.
North of here, California State University, East Bay isn t enrolling any nursing students at all until at least next fall.
Higher education was struggling to keep up with the skyrocketing demand for nurses even before the COVID-19 crisis. Now it s falling further behind.